
WASHINGTON—The U.S. Department of Energy’s (DOE) Office of Energy Dominance Financing (EDF) issued a conditional commitment for a loan of up to $263 million to SHINE Chrysalis, LLC (SHINE) to support the construction of Chrysalis, a high-volume medical isotope production facility in Janesville, Wisconsin. The production facility will create a supply of reliable and secure medical isotopes made with fusion and fission technology. Millions of patients rely on medical isotopes for life-saving diagnostic imaging and cancer treatments, but most of that supply comes from overseas with limited capacity to meet demand.
Utilizing fusion and fission technology, the facility will establish the only domestic commercial supply of molybdenum-99 (Mo-99). Mo-99 is a life-saving medical isotope essential for diagnostic imaging; its decay product of technetium-99m (Tc-99m) is used in over 40,000 medical procedures in the United States each day.
“The SHINE Chrysalis project is vital to improving the nuclear supply chain and contributing to a strong next-generation nuclear workforce while onshoring this critical production and improving national security,” EDF Director Gregory A. Beard said. “Using EDF’s loan authority to further commercialize a project long supported by DOE is Trump’s policy at work: ensuring a reliable and secure domestic supply chain while lowering costs.”
Thanks to President Trump and the Working Families Tax Cut, today’s announcement highlights the Energy Department’s role in advancing President Trump’s Executive Order, Reinvigorating the Nuclear Industrial Base, by maximizing the use of uranium through an innovative recycling process.
This project will support hundreds of construction and operation jobs, contributing to a strong next-generation American nuclear workforce.
SHINE has developed and demonstrated its technology through significant support from the National Nuclear Security Administration (NNSA) over the last 16 years. With NNSA funding, the National Laboratories also played a key role in developing SHINE’s technology.
“SHINE is the key to ending reliance on imports of foreign-produced Mo-99 and ensuring U.S. patients have reliable access to American-made medical isotopes. NNSA’s leadership made this concept a reality, providing funding and technical support from our national laboratories that enabled this innovative U.S. company to go from an idea on paper to a commercial facility that is 75% complete,” said Dr. Matthew Napoli, NNSA’s Deputy Administrator for Defense Nuclear Nonproliferation (DNN). “The EDF conditional loan will get this project across the finish line, and SHINE’s market entry will be a major win for American nuclear medicine, fusion technology, and nuclear nonproliferation leadership.”
EDF is committed to financing American energy and manufacturing projects that meaningfully contribute to U.S. energy security, grid reliability, and lowering costs for all Americans. EDF empowers the private sector to invest in the future, help win the AI race, strengthen American industry, and restore American Energy Dominance.
While this conditional commitment from EDF indicates the Department’s intent to provide a loan to finance the project, DOE and the company must satisfy certain technical, legal, environmental, and financial conditions before the Department enters into definitive financing documents and funds the loan.
###



















